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Abstract 
 DNA methylation is essential for healthy mammalian development 
and function, and is involved in important processes such as suppression of 
repetitive elements, genomic imprinting and carcinogenesis. Thus, aberrant 
DNA methylation is linked to some of the adverse outcomes. DNA 
methylation indicates addition of a methyl (CH3) group to fifth position of a 
cytosine within CpG dinucleotides, which forms clusters called CpG islands. 
DNA methylation patterns are established and maintained by DNA 
methyltransferases (DNMTs). Inactivation of certain tumor suppressor 
genes caused by methylation of the promoter region is widely observed in 
various types of cancer. 
 Epigenetic reprogramming, including DNA demethylation, occurs in 
mammalian primordial germ cells (PGCs) and early embryos, and returns 
the cells to pluripotency. Therefore, DNA methylation in human cells has 
long been thought not to be inherited. However, recent studies have raised 
the possibility that epimutation can occur in human cells.  
 
 
2 
 In chapter 1, I focus on Lynch syndrome, an inherited cancer 
syndrome that is caused by germline mutation of DNA mismatch repair 
(MMR) genes and has an increased risk of colorectal, endometrial and other 
cancers. Recent studies have shown that 25-30% of patients with Lynch 
syndrome have no germline mutation of MMR genes. This raises the 
possibility that epimutation of MMR genes could be an alternative cause of 
Lynch syndrome. Therefore, I investigated epimutation of MMR genes in 
peripheral blood DNA in 106 patients with endometrial cancer, and 
identified patients with Lynch syndrome.  
 Epimutation could be a cause of inherited cancer syndrome and 
sporadic cancer. Some types of cancers show concomitant DNA methylation 
of multiple genes, which is referred to as CpG island methylator phenotype 
(CIMP). In colon cancer, Lynch syndrome and CIMP-positive cancer show 
similar clinicopathological features. However, there are few studies on 
CIMP-positive endometrial cancer, and the causes and features of this 
condition are unknown. In chapter 2, I hypothesized that patients with 
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CIMP-positive endometrial cancer have aberrant DNA methylation 
(epimutation) in normal tissue that is a trigger of carcinogenesis. Therefore, 
I investigated the genome-wide methylation status of DNA from peripheral 
blood cells (PBCs) and cancer tissue in patients with CIMP-positive and 
CIMP-negative endometrial cancer. In DNA from PBCs, the promoter region 
of miR-663a was significantly hypermethylated in CIMP-positive cases 
compared to CIMP-negative cases. 
 These studies provide new knowledge on the relationship between 
epigenetic abnormalities and endometrial carcinogenesis. The findings may 
be applicable to early detection and as a predictive marker. Furthermore, 
DNA methylation is reversible, and future strategies for DNA demethylation 
may contribute to cancer prevention. 
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Abbreviations 
Atypical endometrial hyperplasia: AEH 
CIMP-high: CIMP-H 
CIMP-low: CIMP-L 
CIMP-negative: CIMP(-) 
CpG island methylator phenotype: CIMP  
Differentially methylated CpGs: DMCs 
Differentially methylated regions: DMRs 
DNA methyltransferase: DNMT 
DNA mismatch repair gene: MMR gene 
Methylation specific polymerase chain reaction: MSP 
MicroRNAs: miRNAs 
Next-generation sequencing: NGS 
Peripheral blood cells: PBCs 
Polymerase chain reaction: PCR 
Post-Bisulfite Adaptor Tagging: PBAT 
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Primordial germ cells: PGCs 
Transcription start sites: TSS 
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General Introduction 
 DNA methylation is one of the epigenetic mechanisms used to 
regulate gene expression. Among several mechanisms regulating gene 
expression, DNA methylation is the most common for fixing genes in the “off” 
position. Thus, DNA methylation plays important roles in embryonic 
development, chromosome stability and carcinogenesis. Indeed, the 
relationship between methylation abnormalities and human diseases such 
as cancer, psychiatric disorder and congenital imprinting disorders are 
currently being studied (1). The results of these studies will be important for 
not only treatment of these diseases but also understanding of DNA 
methylation mechanisms and prevention of DNA methylation abnormalities. 
 DNA methylation occurs by the addition of methyl groups to 
cytosine bases in mammalian DNA by DNMTs. In mammals, there are 3 
major DNMTs: DNMT1, DNMT3a and DNMT3b. DNMT3a and DNMT3b 
are de novo DNMTs that show equal affinity for hemi-methylated DNA 
(DNA with one strand methylated) and non-methylated DNA (2). In contrast, 
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DNMT1 is a maintenance DNMT that binds to hemi-methylated DNA at 
CpG sites. After DNA replication, the parent strand remains methylated, 
but the daughter strand is not methylated. DNMT1 binds to these 
hemi-methylated CpGs and methylates the cytosine on the newly 
synthesized daughter strand, and maintains CpG methylation patterns 
through mitosis (3). 
 Unlike animals, plants do not have a separate germline in which 
epigenetic marks are erased and reestablished. Thus, even if DNA 
methylation machinery is restored, epigenetic changes induced in DNA 
methylation abnormalities can be maintained and inherited (4). One of the 
oldest examples of heritable epigenetic change (epimutation) in plants is a 
morphological defect in the development of flower in Linaria vulgaris. The 
mutant phenotype is due to aberrant DNA methylation and transcriptional 
suppression of Lcyc, which is a regulator of dorsoventral asymmetry (Figure 
1). In correlation with the expression recovery by demethylation of Lcyc gene, 
phenotype is restored occasionally (5).  
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 In contrast, methylation patterns of mammalian cells are erased in 
PGCs and at the post-fertilization stage (Figure 2). Therefore, epimutation 
was thought not to occur in mammals. However, there is increasing evidence 
that environmental (nutritional) stimuli can modify DNA methylation and 
affect phenotypic expression of genes. For example, the methylation level of 
the Leptin promoter is significantly increased in oocytes of high-fat diet mice. 
Female offspring from the obese mice showed higher methylation level of 
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c, Face view of a wild-type Linaria  flower compared to a peloric mutant.  
d, Floral diagrams of wild-type (top) and peloric (bottom) flowers showing  
    the relative positions of different organs.  
Adapted from Cubas, P. et al. :Nature, 401: 157-161, 1999  
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Leptin promoter in the liver than normal mice. Expression level of Leptin 
was also significantly decreased in the liver of these offspring (6). Examples 
of epigenetic inheritance in mice raise possibility that occurs similar event in 
humans.  
 
 
 To examine this issue further, I focused on Lynch syndrome, which 
is an inherited cancer syndrome caused by germline mutation of DNA 
conducting standard molecular studies in germ cells and
especially oocytes, which can only be obtained in small
numbers. In this review we report our current understand-
ing of the molecular mechanisms associated with the es-
tablishment of DNA methylation patterns in germ cells,
especially oocytes. We describe which sequences become
methylated, their intrinsic characteristics, and what pro-
tein factors are known to be involved. We shall focus
particularly on specific regions of the genome termed
CpG islands (CGIs) that are associated with key regulatory
elements of gene expression, including many promoters.
We shall discuss recentmajor advances concerning the link
between histone modifications, transcription and the de
novo DNA methylation machinery. Lastly, we shall con-
sider what the future holds in this important and challeng-
ing research area, particularly with the development of
high-throughput sequencing techniques.
The dynamic nature of DNA methylation in germ cells
and its fate in the embryo
Erasure of epigenetic marks in primordial germ cells
Soon after the onset of gastrulation in the mouse embryo,
the precursors of germ cells, or primordial germ cells
(PGCs), emerge from the epiblast (embryonic day E7.25)
as a founder population of <50 cells. They proliferate,
migrate to and colonise the genital ridge, from which the
gonads develop (E10.5-E11.5). Because PGCs originate
from embryonic cells that have started to adopt a somatic
fate, extensive remodelling of histone modifications and
DNA methylation marks towards the requirements of a
germ cell is essential ([3,7–10] for more details). Pre-exist-
ingDNAmethylation patterns are comprehensively erased
during PGC migration, such that by E13.5 the overall
methylation level is <10% [11] (Figure 1); for comparison,
the same study measured the methylation level of the
entire embryo to be >70%. However, some regions escape
epigenetic remodelling in PGCs and retain DNA methyla-
tion marks; for example, retrotransposons of the intracis-
ternal A-particle class (IAPs) remain highly methylated
[11,12]. The consequence of wholesale DNA methylation
erasure in PGCs is that de novo DNA methylation during
germ-cell development takes place on a largely blank slate.
Establishment of specific DNA methylation landscape in
germ cells
Following sex-determination of the embryo (!E12.5), new
DNA methylation patterns are established, differently in
male and female germ cells, resulting in distinct methyla-
tion profiles of mature oocytes and sperm. This asymmetry
is related to the fact that de novo DNA methylation takes
place in distinct cellular contexts in male and female germ
cells (Figure 1). In the female germline de novo methyla-
tion takes place during the postnatal growth phase of
oocytes arrested in meiotic prophase I. In the male germ-
line it initiates before birth in mitotically arrested prosper-
matogonia, before the onset of meiosis (Box 1).
Various sequences are the target of the de novo DNA
methylation machinery in germ cells (Box 2). DNA
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Figure 1. DNAmethylation changes during developmental epigenetic reprogramming. Primordial germ cells (PGCs) emerge in embryos at E7.5 and, concomitant with their
proliferation and migration towards the genital ridge, DNA methylation is globally erased (black line). Following sex-determination, new DNA-methylation landscapes are
established in germ-cell precursors in an asymmetrical fashion in male and female embryos. In the male embryo (blue line), de novomethylation takes place before meiosis
in mitotically arrested cells (G1-phase; prospermatogonia) and is completed before birth. In the female embryo (red line), primary oocytes enter meiosis and arrest in
prophase-I (diplotene stage); DNAmethylation is established after birth during the follicular/oocyte growth phase. At puberty, under specific endocrine triggers, fully-grown
germinal vesicle (GV) oocytes resume the first meiotic division. After extrusion of the first polar body, oocytes arrest in metaphase of the second meiotic division (MII
oocytes) and meiosis is completed only upon fertilisation. Following fertilisation, a new wave of DNA demethylation takes place that is distinct on the parental genomes. In
the zygote, DNA methylation of the paternal genome is rapidly erased by an active mechanism (blue line). Demethylation of the maternal genome is slower (red line) and is
dependent on DNA replication (passive demethylation). These post-fertilisation demethylation events do not include imprinted gDMRs (green dotted line), resulting in
parental-allele-specific methylation of these elements in early embryos and consequent parental-allele-specific expression of associated imprinted genes. Concomitant with
blastocyst implantation and cell-lineage determination, new methylation landscapes become established, associated with cellular differentiation.
Review Trends in Genetics January 2012, Vol. 28, No. 1
34
Figure 2. DNA methylation changes during developmental epigenetic  
                r programming. 
Adapt d from S allwood, SA. et al. : Trands Genet, 28: 33-42, 2012 
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mismatch repair (MMR) genes, most frequently MLH1 and MSH2 (7, 8). 
Lynch syndrome is characterized by increased risk of colorectal, endometrial, 
ovarian and other cancers. In Knudson's two-hit theory, it is required that an 
abnormality (hit) occurs in both alleles of a tumor-suppressor gene for 
disease progression (Figure 3). Germline mutations generally represent the  
 
 
first hit on one allele, while the second hit typically results from a sporadic 
mutation, loss of heterozygosity or methylation. However, germline 
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Figure 3. Knudson’s two-hit theory 
Modified from http://ocw.tufts.edu/data/20/300759/300840_xlarge.jpg 
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mutations of MMR genes are not found in 25-30% of patients with Lynch 
syndrome (9-12). Therefore, it is possible that epimutation of MMR genes 
acts as the first hit in patients with no germline mutation. 
 Evaluation of epimutation of MMR genes to date has been based on 
case studies with insufficient information on families, and epimutation in 
families with endometrial cancer has not been examined. In chapter 1, I 
explored epimutation in cases of endometrial cancer and identified patients 
with Lynch syndrome.  
 Epimutation could be a cause of inherited cancer syndrome and 
sporadic cancer. Aberrant DNA hypermethylation in CpG island is a 
hallmark of cancer and is characterized by tumor-specific hypermethylation 
of numerous CpG islands (13). MLH1 methylation is also observed in cases of 
sporadic colorectal and endometrial cancer (14). These cancers show the 
same phenotype of mismatch repair defect and clinicopathologic 
characteristics similar to Lynch syndrome. Such sporadic colorectal cancer 
also has a close relationship with cancer with a CpG island methylator 
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phenotype (CIMP) (15) (Figure 4). CIMP was first proposed by Toyota et al. 
in 1999 (16). They defined a subgroup of colorectal cancers with concurrent  
 
 
multiple promoter hypermethylation of tumor-related genes as CIMP.  
CIMP has subsequently been reported in gastric (17, 18), lung (19, 20), liver 
(21) and ovarian (22) cancer. Recent studies revealed that CIMP is 
negatively associated with genetic mutations in colorectal cancers (23, 24), 
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Figure 4. Relationship between Lynch syndrome and CIMP-positive  
                endometrial cancer
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which suggests that it can provide an alternative oncogenic pathway. This 
findings supported that epimutation may be one of the cause of CIMP 
positive cancer. Thus, I hypothesized that normal tissue of CIMP-positive 
endometrial cancer has features which are prone to get DNA methylation, 
and that such features play important roles in carcinogenesis in this cancer. 
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General Discussion 
 Lynch syndrome is one of the most prevalent hereditary cancer 
syndromes in humans and is caused by inherited defects in MMR genes (89, 
90). In the last two decades, increased appreciation of epigenetic 
mechanisms in tumorigenesis and identification of constitutional 
epimutations underlying Lynch syndrome have laid the foundation for the 
epigenetic era (11). Epimutation is regarded as secondary if induced by an 
adjacent genetic alteration, and otherwise as primary (33). Lynch syndrome 
offers one of the first examples of cancer-associated constitutional 
epimutation, namely primary epimutation of MLH1 (11). Recent 
observations of constitutional epimutations as the first hit and promoter 
methylation as the second hit in Lynch syndrome emphasize the increasing 
significance of epigenetic events, especially as methylation as the second hit 
is associated with a more generalized CIMP in tumors (91). 
 CIMP was first explained by Toyota et al. in 1999 (16). CIMP occurs 
in a subset of colorectal cancers that are characterized by vast 
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hypermethylation of promoter CpG island sites, resulting in inactivation of 
several tumor suppressor genes or other tumor-related genes (92). Many 
studies have found an association between CIMP status and other important 
epidemiological and molecular factors, such as smoking, age and genetic 
mutations (93-95). 
 In chapter 1, I tried to identify MMR genes epimutation positive 
patients from 106 endometrial cancer patients. According to our preliminary 
experiment, 1% of endometrial cancer patients show MLH1 epimutation, but 
no cases of epimutation-positive endometrial cancer were found in this 
study.   
 I also identified two patients with Lynch syndrome among the 106 
patients with endometrial cancer, based on the Amsterdam II criteria and 
revised Bethesda guidelines (diagnostic criteria for Lynch syndrome using 
family and personal history). One of these patients had a novel MSH6 
nonsense mutation. Since colon cancer in patients with Lynch syndrome is 
characterized by mutations in MLH1 and MSH2, rather than MSH6, 
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endometrial cancer with Lynch syndrome may have a different 
carcinogenetic pathway. 
 Next, I focused on the relationship between epigenetic alteration 
and sporadic endometrial carcinogenesis. Many studies have shown that 
DNA methylation is related to endometrial cancer, especially in the early 
stages of carcinogenesis. Moreover, some types of cancer, including 
endometrial cancer, show a CIMP phenotype. These findings suggest that 
DNA methylation plays important roles in carcinogenesis and in cancer 
phenotypes, but it is still unclear whether such DNA methylation is a cause 
or a result of cancer. 
 I succeeded in identifying aberrant DNA methylation, which is a 
potential cause of CIMP-positive endometrial carcinogenesis. The MiR-663a 
promoter region in PBC DNA of CIMP-H patients was significantly 
hypermethylated compared to that of CIMP(-) patients. Consistent with this 
methylation pattern, miR-663a expression in PBCs of CIMP-H patients was 
lower than that in CIMP(-) patients. The miR-663a promoter region is a 
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hypomethylated region in normal human adult tissues, and therefore 
miR-663a DNA methylation identified in this study may be a novel 
epimutation candidate. 
 This study provides new findings on the involvement of epigenetic 
abnormalities in hereditary and sporadic endometrial cancer. Detection of 
abnormal DNA methylation using a blood specimen can be performed 
quickly and conveniently, and thus is useful as a cancer prediction and 
diagnostic marker. Furthermore, since methylation of DNA is reversible, 
site-specific demethylation may contribute to prevention of cancer. 
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